Investments
182Portfolio Exits
58Funds
6Service Providers
3About Aisling Capital
Aisling Capital, a private equity firm, believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. The Firm's goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Want to inform investors similar to Aisling Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Aisling Capital News
Aug 30, 2023
Aug. 30, 2023 “Sometimes the market gets ahead of the science,” said Dennis Purcell, founder of Aisling Capital, pointing to the way backers of genomics firms “went nuts” in the early 2000s. “I think we’re in a position today where the science is ahead of where the market is.” The remarks by venture capital (VC) expert Purcell came during a virtual salon hosted Aug. 30 by Demy-Colton and titled “VC Trends in Healthcare Investing: Current Pulse Check.” Panelists acknowledged the currently unfavorable financing environment but sounded upbeat about the industry’s path forward.
Aisling Capital Investments
182 Investments
Aisling Capital has made 182 investments. Their latest investment was in Compass Pathways as part of their PIPE on August 8, 2023.
Aisling Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
8/16/2023 | PIPE | Compass Pathways | $125M | Yes | 2 | |
9/12/2022 | Series C | Forge Biologics | $90M | Yes | Aisling Capital, Drive Capital, and Undisclosed Investors | 8 |
3/29/2022 | Series B | Dren Bio | $65M | Yes | 8VC, Aisling Capital, Alexandria Venture Investments, ArrowMark Partners, BVF Partners, HBM Healthcare Investments, Mission BioCapital, Pfizer, Revelation Partners, SR One, Taiho Ventures, and Undisclosed Investors | 1 |
11/3/2021 | Series B - II | |||||
9/23/2021 | Series A |
Date | 8/16/2023 | 9/12/2022 | 3/29/2022 | 11/3/2021 | 9/23/2021 |
|---|---|---|---|---|---|
Round | PIPE | Series C | Series B | Series B - II | Series A |
Company | Compass Pathways | Forge Biologics | Dren Bio | ||
Amount | $125M | $90M | $65M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | Aisling Capital, Drive Capital, and Undisclosed Investors | 8VC, Aisling Capital, Alexandria Venture Investments, ArrowMark Partners, BVF Partners, HBM Healthcare Investments, Mission BioCapital, Pfizer, Revelation Partners, SR One, Taiho Ventures, and Undisclosed Investors | |||
Sources | 2 | 8 | 1 |
Aisling Capital Portfolio Exits
58 Portfolio Exits
Aisling Capital has 58 portfolio exits. Their latest portfolio exit was Paratek Pharmaceuticals on September 20, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/20/2023 | Take Private | 10 | |||
6/25/2021 | IPO | Public | 6 | ||
6/24/2021 | IPO | Public | 17 | ||
Date | 9/20/2023 | 6/25/2021 | 6/24/2021 | ||
|---|---|---|---|---|---|
Exit | Take Private | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 10 | 6 | 17 |
Aisling Capital Fund History
6 Fund Histories
Aisling Capital has 6 funds, including Aisling Capital V.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/25/2020 | Aisling Capital V | Late-Stage Venture Capital | Open | $144.15M | 2 |
11/2/2017 | Aisling Capital Healthcare | ||||
7/19/2016 | Aisling Capital IV | ||||
12/31/2008 | Aisling Capital III LP | ||||
12/22/2005 | Aisling Capital II LP |
Closing Date | 6/25/2020 | 11/2/2017 | 7/19/2016 | 12/31/2008 | 12/22/2005 |
|---|---|---|---|---|---|
Fund | Aisling Capital V | Aisling Capital Healthcare | Aisling Capital IV | Aisling Capital III LP | Aisling Capital II LP |
Fund Type | Late-Stage Venture Capital | ||||
Status | Open | ||||
Amount | $144.15M | ||||
Sources | 2 |
Aisling Capital Service Providers
3 Service Providers
Aisling Capital has 3 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Accounting Firm | |||
Service Provider | |||
|---|---|---|---|
Associated Rounds | |||
Provider Type | Accounting Firm | ||
Service Type |
Partnership data by VentureSource
Aisling Capital Team
9 Team Members
Aisling Capital has 9 team members, including current Chief Financial Officer, Lloyd E. Appel.
Name | Work History | Title | Status |
|---|---|---|---|
Lloyd E. Appel | Chief Financial Officer | Current | |
Name | Lloyd E. Appel | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Financial Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
